Armodafinil is a prescription wakefulness-promoting drug sold as Nuvigil. It is the R-enantiomer of modafinil (Provigil): modafinil is a 1:1 mix of two mirror-image molecules, and armodafinil is the purified “R” half of that mix. The FDA approved Nuvigil in June 2007 to improve wakefulness in adults with excessive sleepiness from obstructive sleep apnea (OSA), narcolepsy or shift work disorder.
The single most important practical fact is that armodafinil does not work differently from modafinil; it is the longer-lasting half of it. Both drugs have a similar terminal half-life, but armodafinil skips the fast-cleared S-enantiomer, so blood levels stay higher later in the day and total exposure is higher per milligram. It carries the same serious rash warning as modafinil, is a US Schedule IV controlled substance, and is prohibited in competition under the WADA 2026 list.
This page summarizes what the FDA label, the clinical trials and regulators report. It is for education only and is not medical advice.
| Property | Detail |
|---|---|
| Drug class | Wakefulness-promoting agent; indirect dopamine agonist (dopamine reuptake inhibitor) |
| Brand / approval | Nuvigil (Cephalon, a Teva company), FDA approval June 15, 2007 (NDA 021875); generics marketed |
| Route | Oral tablet |
| Strengths | 50, 150, 200 and 250 mg |
| Labeled adult dose | OSA or narcolepsy: 150–250 mg once in the morning; shift work disorder: 150 mg about 1 h before the shift |
| Half-life | ≈15 h (label); about 13 h in pooled single-dose studies |
| Time to peak | ≈2 h fasted; food can delay it by 2–4 h |
| Key warning | Serious rash including Stevens-Johnson syndrome; stop at the first sign of rash |
| US status | Prescription only; Schedule IV (as an isomer of modafinil) |
| WADA status | Prohibited in competition (S6.A non-specified stimulant, as an optical isomer of modafinil) |
What it is
Armodafinil’s chemical name is 2-[(R)-(diphenylmethyl)sulfinyl]acetamide, formula C15H15NO2S, molecular weight 273.35 (Nuvigil label; PubChem). The chiral center is the sulfur atom of the sulfinyl group. Modafinil contains equal parts of the R- and S-forms; armodafinil contains only the R-form.
| Feature | Armodafinil (Nuvigil) | Modafinil (Provigil) |
|---|---|---|
| Composition | R-enantiomer only | 1:1 racemic mixture of R and S |
| Half-life of each enantiomer | R: ≈15 h | R: ≈15 h; S: ≈4 h |
| Labeled dose, OSA or narcolepsy | 150–250 mg once daily | 200 mg once daily |
| Labeled dose, shift work disorder | 150 mg | 200 mg |
| Approved US indications | Excessive sleepiness in OSA, narcolepsy, shift work disorder | Same three indications |
Sources for the table: the Nuvigil label, the Provigil label and Darwish et al., Clin Ther 2010. The Provigil label notes that the two enantiomers do not convert into each other, and that at steady state about 90% of the modafinil left in the blood before the next dose is the R-form.
The Nuvigil label states that the R- and S-enantiomers have similar pharmacological actions in animals (Nuvigil label). The difference between the two drugs is therefore mainly about how long the active drug stays in the blood, not a different mechanism.
Mechanism
The label says the exact mechanism is unknown. Armodafinil binds the dopamine transporter (DAT) and blocks dopamine reuptake, which makes it an indirect dopamine agonist. In mice engineered to lack DAT, modafinil had no wake-promoting effect. In vitro, modafinil raised extracellular dopamine without increasing dopamine release, and unlike amphetamine’s, its wake-promoting effect in rats was not blocked by the dopamine antagonist haloperidol (Nuvigil label).
Human imaging supports the DAT link. In a positron emission tomography (PET) study of 12 adults, armodafinil 100 mg occupied about 34–40% of striatal dopamine transporters, and 250 mg occupied about 61–65%, measured 1 and 2.5 h after dosing (Spencer et al., Biol Psychiatry 2010).
Pharmacokinetics
The Nuvigil label reports linear, dose-proportional kinetics from 50 to 400 mg, with steady state reached within 7 days (Nuvigil label).
| Parameter | Value (label) |
|---|---|
| Time to peak | ≈2 h fasted; delayed ≈2–4 h with food |
| Effect of food on total exposure | Minimal, but onset and time course can shift |
| Apparent volume of distribution | ≈42 L |
| Terminal half-life | ≈15 h |
| Oral clearance | ≈33 mL/min |
| Steady-state exposure vs single dose | 1.8 times |
| Main metabolic routes | Amide hydrolysis (largest), then sulfone formation by CYP3A4/5 |
| Major plasma metabolites | R-modafinil acid and modafinil sulfone (not thought to be CNS-active) |
How it differs from modafinil
The idea that armodafinil “lasts longer because it has a longer half-life” is only partly right. In pooled single-dose studies in healthy adults, armodafinil and modafinil both had a terminal half-life of about 13 hours and similar peak levels (Darwish et al., Clin Drug Investig 2009). The difference is the shape of the curve. After its peak, modafinil declines in two phases because the S-enantiomer (half-life about 4 h) is cleared quickly; armodafinil declines in a single phase.
| Comparison at equal milligram doses | Result |
|---|---|
| Single dose, healthy adults (dose-normalized to 200 mg) | Armodafinil AUC 33–40% higher; similar Cmax and half-life (Darwish 2009) |
| Steady state, 200 mg vs 200 mg (label) | Armodafinil Cmax ≈37% higher, AUC ≈70% higher (Nuvigil label) |
| Patients with CPAP-treated OSA, n = 42, crossover | Multiple-dose AUC ratio 1.69 (95% CI 1.65–1.72); Cmax ratio 1.37 (95% CI 1.33–1.41); not bioequivalent by FDA criteria (Darwish et al., Clin Ther 2010) |
| 50 mg armodafinil vs 100 mg modafinil | R-enantiomer concentration curves nearly superimposable (label) |
In other words, armodafinil 50 mg delivers about the same R-enantiomer exposure as modafinil 100 mg, and milligram for milligram armodafinil gives higher late-day levels. In a sleep-loss study of 107 healthy men, armodafinil 200 mg gave higher plasma levels 6–14 h after dosing than modafinil 200 mg, with longer wakefulness test latencies and fewer attention lapses over that window (Dinges et al., Curr Med Res Opin 2006). Higher blood levels have not translated into proven superior efficacy. In a 12-week double-blind trial in India, 211 patients with shift work disorder received armodafinil 150 mg or modafinil 200 mg before night shifts; responder rates were similar (72% vs 74%, p = 0.76), as were adverse event rates (Tembe et al., Neurol Res Int 2011).
Specific populations
- Older adults: exposure was about 15% higher in people aged 65 and over, and 27% higher in those 75 and over. The label suggests considering lower doses.
- Severe liver impairment: with modafinil in cirrhosis, oral clearance fell by about 60% and steady-state levels doubled. The label calls for a reduced Nuvigil dose.
- Severe kidney failure: modafinil kinetics were not significantly changed, but exposure to the inactive acid metabolite rose 9-fold.
All three points come from the Nuvigil label.
Approved medical use
Nuvigil is indicated to improve wakefulness in adults with excessive sleepiness associated with OSA, narcolepsy or shift work disorder (Nuvigil label; Drugs@FDA, NDA 021875).
| Indication | Labeled dose | Label notes |
|---|---|---|
| OSA | 150–250 mg once daily in the morning | Treats sleepiness, not the airway obstruction. CPAP should be tried fully first and continued. No consistent evidence that 250 mg adds benefit over 150 mg. |
| Narcolepsy | 150–250 mg once daily in the morning | Same dose range as OSA |
| Shift work disorder | 150 mg about 1 h before the work shift | Only patients symptomatic for at least 3 months were studied |
| Severe hepatic impairment | Reduced dose | No specific number given |
Armodafinil is not approved for children, and the label states it has not been studied in pediatric patients. It is not approved for jet lag, depression, fatigue or cognitive enhancement.
What the research shows
Pivotal trials for the approved indications
All four pivotal trials were 12-week, double-blind, placebo-controlled studies. The primary outcomes were sleep latency on the Maintenance of Wakefulness Test (MWT, how long a person can stay awake in a quiet room) or Multiple Sleep Latency Test (MSLT, how fast a person falls asleep when asked to nap), plus the Clinical Global Impression of Change (CGI-C, a clinician’s rating of overall improvement).
| Trial | Population, n | Arms | Sleep latency change from baseline | CGI-C improved |
|---|---|---|---|---|
| OSA I (Roth et al., Clin Ther 2006) | CPAP-adherent OSA with residual sleepiness, n = 395 | 150 mg, 250 mg, placebo | MWT +1.7 and +2.2 min vs −1.7 min | 71% and 74% vs 37% |
| OSA II (Hirshkowitz et al., Respir Med 2007) | CPAP-adherent OSA, n = 263 randomized | 150 mg, placebo | MWT +2.3 vs −1.3 min | 71% vs 53% |
| Narcolepsy (Harsh et al., Curr Med Res Opin 2006) | Narcolepsy, n = 196 | 150 mg, 250 mg, placebo | MWT +1.3 and +2.6 min vs −1.9 min | 69% and 73% vs 33% |
| Shift work disorder (Czeisler et al., Mayo Clin Proc 2009) | Night-shift workers with chronic SWD, n = 254 | 150 mg, placebo | Night MSLT +3.1 vs +0.4 min | 79% vs 59% |
Figures are the label’s Table 3 and Table 4 (Nuvigil label). All comparisons were significant against placebo (p under 0.05). Night-time (or, for shift workers, daytime) sleep on polysomnography was not affected.
The absolute effects are modest. In the shift work trial, mean night-time sleep latency rose from 2.3 to 5.3 minutes on armodafinil, compared with 2.4 to 2.8 minutes on placebo (Czeisler et al., 2009). The label itself warns that patients’ wakefulness may not return to normal.
Meta-analyses in OSA
- A 2016 meta-analysis of 5 armodafinil RCTs (1,009 patients) found the Epworth Sleepiness Scale (ESS, a 0–24 self-rated sleepiness score) improved by 2.63 points (95% CI 1.85–3.4) and MWT latency by 2.71 min (95% CI 0.04–5.37) versus placebo. Modafinil trials showed similar effects (Kuan et al., Clin Ther 2016).
- A second meta-analysis pooled modafinil and armodafinil (10 trials, 1,466 patients): ESS improved by 2.2 points (95% CI 1.5–2.9) and MWT by 3 min (95% CI 2.1–3.8). The drugs tripled adverse events and doubled withdrawals due to adverse events, without increasing serious adverse events (Chapman et al., Eur Respir J 2016).
Uses that were studied but not approved
| Use | Trial | Result |
|---|---|---|
| Jet lag | Phase 3, n = 427, 50 or 150 mg after a 6-time-zone eastward flight (Rosenberg et al., Mayo Clin Proc 2010) | 150 mg raised MSLT latency to 11.7 vs 4.8 min on placebo; headache in 27% and nausea in 13% on 150 mg. Not an approved indication. |
| Bipolar I depression (add-on) | Phase 2, n = 257 (Calabrese et al., J Clin Psychiatry 2010) | Primary ANCOVA analysis not significant (p = 0.074) |
| Bipolar I depression (add-on) | Phase 3, n = 433 (Calabrese et al., J Clin Psychiatry 2014) | 150 mg beat placebo on the primary score (effect size d = 0.28) |
| Bipolar I depression (add-on) | Phase 3, n = 492 (Ketter et al., J Affect Disord 2015) | Primary outcome not significant (p = 0.13) |
| Bipolar I depression (add-on) | Phase 3, n = 399 (Frye et al., Int J Bipolar Disord 2015) | Primary outcome not significant |
| Fatigue after high-grade glioma | Phase 3, n = 328, 150 or 250 mg vs placebo (Porter et al., JAMA Oncol 2022) | No benefit: 28% and 28% vs 30% had meaningful fatigue reduction |
A meta-analysis of the four armodafinil bipolar trials plus one modafinil trial found a small pooled benefit for response (RR 1.18, 95% CI 1.01–1.37) and remission (RR 1.38, 95% CI 1.10–1.73), with no increase in mood switching (Nunez et al., Bipolar Disord 2020). Two of the three phase 3 trials still missed their primary endpoint, and the drug was not approved for this use.
Healthy people and “cognitive enhancement”
Studies in healthy volunteers are short and mostly done under sleep deprivation. In the 107-man sleep-loss study, all armodafinil doses (100–300 mg) improved wakefulness and reduced attention lapses versus placebo, but also lowered sleep efficiency and raised blood pressure, and some participants reported a fast heartbeat or palpitations (Dinges et al., 2006). There are no long-term controlled trials of armodafinil as a cognitive enhancer in rested, healthy adults. The label also states that Nuvigil is not a replacement for sleep.
Side effects and risks
Common side effects
In pooled placebo-controlled trials (645 on Nuvigil, 445 on placebo), the most common adverse reactions were (Nuvigil label):
| Adverse reaction | 150 mg | 250 mg | Placebo |
|---|---|---|---|
| Headache | 14% | 23% | 9% |
| Nausea | 6% | 9% | 3% |
| Insomnia | 4% | 6% | 1% |
| Dry mouth | 2% | 7% | under 1% |
| Rash | 1% | 4% | under 1% |
| Depression | 1% | 3% | under 1% |
Headache, rash, depression, dry mouth, insomnia and nausea were dose-related. Overall, 7% of patients on Nuvigil stopped because of side effects, versus 4% on placebo. Mean levels of the liver enzymes GGT and alkaline phosphatase rose on Nuvigil, though few values left the normal range.
Serious rash, including Stevens-Johnson syndrome
This is the label’s first warning. Serious rash requiring hospitalization has been reported with both armodafinil and modafinil, including rare cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), severe reactions in which skin and mucous membranes blister and peel (Nuvigil label).
- In pediatric modafinil trials, rash leading to discontinuation occurred in about 0.8% (13 of 1,585) of children, including 1 possible SJS case; none occurred in 380 children on placebo.
- Serious rash has appeared 1 day to 2 months after starting, with isolated cases after about 3 months.
- No factor, including dose or duration, predicts which rash will become serious. The label says to stop the drug at the first sign of rash, mouth sores, blistering or ulceration unless the rash is clearly unrelated, and notes that stopping may not prevent a life-threatening course.
A published case describes SJS in a 21-year-old woman after starting armodafinil (Holfinger et al., J Clin Sleep Med 2018).
DRESS, angioedema and anaphylaxis
Drug reaction with eosinophilia and systemic symptoms (DRESS, a multi-organ allergic reaction with fever, rash, swollen glands and organ inflammation) has been reported with Nuvigil, including one fatal case about 3 weeks after starting. Angioedema (swelling of the face, lips, tongue or throat) and anaphylaxis have also been reported. Hypersensitivity to modafinil or armodafinil is a contraindication (Nuvigil label).
Psychiatric effects
In pre-approval trials, anxiety, agitation, nervousness and irritability led to discontinuation in 1.2% on Nuvigil versus 0.3% on placebo, and depression in 0.6% versus 0.2%. Cases of suicidal ideation were observed. After approval, mania, delusions, hallucinations, suicidal ideation and aggression were reported at daily doses of 50–450 mg, mostly but not only in people with prior psychiatric history (Nuvigil label).
Heart and blood pressure
In trials of up to 3 months, Nuvigil raised mean systolic and diastolic blood pressure by 1.2–4.3 mmHg and pulse by 0.9–3.5 beats per minute versus placebo. Slightly more patients needed new or increased blood pressure medication (2.9% vs 1.8%). The label advises against use in people with left ventricular hypertrophy, or mitral valve prolapse with prior stimulant-related symptoms, and caution in known cardiovascular disease.
Abuse, dependence and overdose
Armodafinil is a Schedule IV controlled substance. The label describes reported abuse (euphoria, escalating doses), diversion, tolerance, and withdrawal after abrupt stopping, including shaking, sweating, nausea, confusion, aggression, atrial fibrillation and, post-marketing, withdrawal seizures. Fatal overdoses have been reported with modafinil alone and with Nuvigil or modafinil combined with other drugs. There is no specific antidote (Nuvigil label).
Pregnancy
The label warns of possible fetal harm based on animal data, and reports intrauterine growth restriction and miscarriage in association with armodafinil and modafinil. In the manufacturer’s final 14-year pregnancy registry (191 pregnancies), major congenital malformations occurred in 13.1% of prospectively followed live births (95% CI 8.0–20.0), against a population reference rate of 3% (Kaplan et al., Neurol Clin Pract 2025). The registry was small and uncontrolled, but the signal has persisted.
Interactions
Armodafinil is a moderate inducer of CYP3A4 and a moderate inhibitor of CYP2C19, the two liver enzymes behind most of its interactions (Darwish et al., Clin Pharmacokinet 2008; Nuvigil label).
| Interacting drug or class | Effect | Measured data / label advice |
|---|---|---|
| Hormonal contraceptives (e.g. ethinyl estradiol) | Lower contraceptive levels via CYP3A4 induction | Use an alternative or additional non-hormonal method during treatment and for 1 month after stopping |
| Cyclosporine | Lower blood levels | Monitor levels and adjust dose |
| Midazolam, triazolam (CYP3A substrates) | Lower exposure | 250 mg cut oral midazolam AUC by 32% and IV midazolam by 17% |
| Quetiapine | Lower exposure | Mean exposure fell ≈29% with 250 mg; label says no dose change needed |
| Omeprazole, diazepam, phenytoin, propranolol, clomipramine (CYP2C19 substrates) | Higher exposure | 400 mg raised omeprazole exposure by 40% (label) or 38% (published study) |
| Warfarin | Possible change in effect | More frequent INR monitoring |
| MAO inhibitors | No interaction data | Use with caution |
| Strong CYP3A4 inducers or inhibitors (carbamazepine, rifampin, ketoconazole) | Could change armodafinil levels | Partial CYP3A role in its metabolism |
Armodafinil did not meaningfully affect CYP1A2 in a caffeine probe study (Darwish et al., 2008).
Legal status and use outside medicine
- United States: Nuvigil is labeled “C-IV.” The DEA’s Schedule IV list names modafinil, including its salts, isomers and salts of isomers, which covers armodafinil as the R-isomer (21 CFR 1308.14).
- Sport: The WADA 2026 Prohibited List names modafinil (and adrafinil, flmodafinil and fladrafinil) under S6.A non-specified stimulants, prohibited in competition. The S6 section states that all optical isomers of listed stimulants are prohibited, which includes armodafinil (WADA 2026 Prohibited List).
Armodafinil appears in performance and “nootropic” circles mainly as a longer-acting alternative to modafinil. The controlled evidence covers sleep disorders and short sleep-deprivation studies, not routine use by rested, healthy adults.
Key takeaways
- The R-half of modafinil. Armodafinil is the purified R-enantiomer; both enantiomers act similarly, so the difference is pharmacokinetic, not a different mechanism.
- Same half-life, different curve. Both drugs have a terminal half-life of roughly 13–15 h, but without the fast-cleared S-form armodafinil keeps higher late-day levels and gives about 70% more steady-state exposure than the same milligram dose of modafinil.
- Modest, proven benefit in three sleep disorders. OSA meta-analyses found about 2.6 points better on the Epworth scale and 2.7 minutes longer on the wakefulness test than placebo; it is approved only for sleepiness from OSA, narcolepsy and shift work disorder.
- Rash is the key safety signal. Serious rash, SJS/TEN and DRESS are rare but can be fatal and cannot be predicted; the label calls for stopping at the first sign of rash.
- Real interactions. CYP3A4 induction can make hormonal contraceptives fail during use and for a month after; CYP2C19 inhibition raises levels of drugs such as omeprazole and diazepam.
- Controlled and banned in sport. It is Schedule IV in the US and prohibited in competition by WADA as an optical isomer of modafinil.
Sources
- Cephalon, LLC. Nuvigil (armodafinil) tablets, C-IV, prescribing information. Revised December 2022. DailyMed.
- Food and Drug Administration. Drugs@FDA: Nuvigil (armodafinil), NDA 021875, original approval June 15, 2007. FDA.
- National Center for Biotechnology Information. PubChem Compound Summary: Armodafinil, CID 9690109. PubChem.
- Spencer TJ, Madras BK, Bonab AA, et al. A positron emission tomography study examining the dopaminergic activity of armodafinil in adults using [¹¹C]altropane and [¹¹C]raclopride. Biol Psychiatry. 2010;68(10):964–970. PubMed.
- Darwish M, Kirby M, Hellriegel ET, et al. Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half-lives: analysis of data from three randomized, single-dose, pharmacokinetic studies. Clin Drug Investig. 2009;29(9):613–623. PubMed.
- Darwish M, Kirby M, D’Andrea DM, et al. Pharmacokinetics of armodafinil and modafinil after single and multiple doses in patients with excessive sleepiness associated with treated obstructive sleep apnea: a randomized, open-label, crossover study. Clin Ther. 2010;32(12):2074–2087. PubMed.
- Dinges DF, Arora S, Darwish M, et al. Pharmacodynamic effects on alertness of single doses of armodafinil in healthy subjects during a nocturnal period of acute sleep loss. Curr Med Res Opin. 2006;22(1):159–167. PubMed.
- Roth T, White D, Schmidt-Nowara W, et al. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. Clin Ther. 2006;28(5):689–706. PubMed.
- Hirshkowitz M, Black JE, Wesnes K, et al. Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome. Respir Med. 2007;101(3):616–627. PubMed.
- Harsh JR, Hayduk R, Rosenberg R, et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin. 2006;22(4):761–774. PubMed.
- Czeisler CA, Walsh JK, Wesnes KA, et al. Armodafinil for treatment of excessive sleepiness associated with shift work disorder: a randomized controlled study. Mayo Clin Proc. 2009;84(11):958–972. PubMed.
- Kuan YC, Wu D, Huang KW, et al. Effects of modafinil and armodafinil in patients with obstructive sleep apnea: a meta-analysis of randomized controlled trials. Clin Ther. 2016;38(4):874–888. PubMed.
- Chapman JL, Vakulin A, Hedner J, et al. Modafinil/armodafinil in obstructive sleep apnoea: a systematic review and meta-analysis. Eur Respir J. 2016;47(5):1420–1428. PubMed.
- Rosenberg RP, Bogan RK, Tiller JM, et al. A phase 3, double-blind, randomized, placebo-controlled study of armodafinil for excessive sleepiness associated with jet lag disorder. Mayo Clin Proc. 2010;85(7):630–638. PubMed.
- Calabrese JR, Ketter TA, Youakim JM, et al. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry. 2010;71(10):1363–1370. PubMed.
- Calabrese JR, Frye MA, Yang R, et al. Efficacy and safety of adjunctive armodafinil in adults with major depressive episodes associated with bipolar I disorder: a randomized, double-blind, placebo-controlled, multicenter trial. J Clin Psychiatry. 2014;75(10):1054–1061. PubMed.
- Ketter TA, Yang R, Frye MA. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder. J Affect Disord. 2015;181:87–91. PubMed.
- Frye MA, Amchin J, Bauer M, et al. Randomized, placebo-controlled, adjunctive study of armodafinil for bipolar I depression: implications of novel drug design and heterogeneity of concurrent bipolar maintenance treatments. Int J Bipolar Disord. 2015;3(1):34. PubMed.
- Nunez NA, Singh B, Romo-Nava F, et al. Efficacy and tolerability of adjunctive modafinil/armodafinil in bipolar depression: a meta-analysis of randomized controlled trials. Bipolar Disord. 2020;22(2):109–120. PubMed.
- Porter AB, Liu H, Kohli S, et al. Efficacy of treatment with armodafinil for cancer-related fatigue in patients with high-grade glioma: a phase 3 randomized clinical trial. JAMA Oncol. 2022;8(2):259–267. PubMed.
- Holfinger S, Roy A, Schmidt M. Stevens-Johnson syndrome after armodafinil use. J Clin Sleep Med. 2018;14(5):885–887. PubMed.
- Kaplan S, Carneal-Frazer N, Braverman DL, et al. Pregnancy and fetal outcomes following prenatal exposure to modafinil and/or armodafinil: a 14-year registry study. Neurol Clin Pract. 2025;15(6):e200551. PubMed.
- Darwish M, Kirby M, Robertson P Jr, et al. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. Clin Pharmacokinet. 2008;47(1):61–74. PubMed.
- Tembe DV, Dhavale A, Desai H, et al. Armodafinil versus modafinil in patients of excessive sleepiness associated with shift work sleep disorder: a randomized double blind multicentric clinical trial. Neurol Res Int. 2011;2011:514351. PubMed.
- Cephalon, LLC. Provigil (modafinil) tablets, C-IV, prescribing information. DailyMed.
- US Drug Enforcement Administration. Schedule IV. 21 CFR 1308.14(f)(7). eCFR.
- World Anti-Doping Agency. The 2026 Prohibited List, section S6 Stimulants. WADA 2026 Prohibited List.